CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

NCT04231851 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia (AML) Due to Therapy
Acute Myeloid Leukemia With Myelodysplasia-Related Changes

Interventions

DRUG: Glasdegib
DRUG: CPX-351

Sponsor

University of California, Irvine

Collaborators

[object Object]
[object Object]